Although subgroup analyses from large randomised premarketing studies have shown that Apomorphine SL enhances the percentage of erections firm enough for sexual intercourse in diabetic men, the clinical role of the drug in this patient population remains to be elucidated. The aim of the present study was to assess the efficacy of Apomorphine SL in diabetic males with erectile dysfunction (ED) and to identify factors predicting those who may benefit from the treatment. A total of 130 diabetic patients were randomised to receive either four tablets of 3 mg Apomorphine or a matching placebo. Assessments of efficacy comprised the erectile function (EF) domain of the International Index of Erectile Function (IIEF) and the one-item global efficacy question (GEQ). Patients with both a positive response to the GEQ and an improvement of at least 5 points in the EF domain of the IIEF were considered responders and subanalysed by several parameters indicative of the severity of both ED and diabetes. Response rate was 17% after placebo and 22% after Apomorphine SL. The EF domain of the IIEF and both questions 3 and 4 scores did not significantly improve in either of the two arms over the baseline. A younger age and a lower Hb1Ac were significantly linked to the status of responder in the Apomorphine arm. Apomorphine SL failed to show a statistically significant benefit over a placebo, but 22% of patients had a clinically significant erectile response. These figures seem to suggest that the drug has a limited use for ED diabetic patients.
Introduction
Diabetic men are up to twice as likely to experience erectile dysfunction (ED) as nondiabetic men. 1 Erectile difficulties are experienced at a significantly younger age by diabetic patients, resulting in a more impaired quality of life than in the nondiabetic population. 2 Both structural and molecular abnormalities account for the organic onset of ED in diabetes. Hypoxia-induced loss of smooth muscle and fibrosis result in decreased compliance of the cavernosal tissue. 3 Endothelial cell damage due to increased production of advanced glycation end products 4 and premature death of nonadrenergic, noncolinergic nerve endings in the penis lower NO concentrations in cavernous tissue. 5 The reduced availability of the second messenger NO decreases the production of cyclic guanosin monophosphate, which is the power source for the relaxation of the cavernosal smooth muscle. The mechanism of action of phosphodiesterase type 5 inhibitors, a class of oral agents extensively used in the treatment of diabetic ED, relies on the amplification of the response to NO stimulation. 6 Suboptimal NO levels may explain the lower efficacy of these molecules in diabetes patients. 7 A search for an alternative oral agent in the treatment of diabetic ED is therefore advisable.
Apomorphine SL, a centrally acting selective D1, D2-like dopamine agonist, has a unique mechanism of action in that it primarily enhances normal neurological signalling in response to sexual stimuli. As a result, more signals are delivered from the nervous system to the periphery to effect penile smooth muscle relaxation. 8 Premarketing phase III studies on a large series of ED patients reported a statistically significant improvement in erectile function (EF) of 2 and 3 mg Apomorphine SL over a placebo. 9 Subgroup analyses by diabetes comorbidity revealed no notable difference in efficacy from the overall analysis. 10, 11 To our knowledge, the clinical utility of this centrally acting drug on the ED of diabetic patients has not yet been defined since no previous study has specifically focused on a series of impotent diabetic patients. The primary study end point was to determine the number of patients showing a clinical response to Apomorphine SL, compared to those responding to a placebo, and to identify clinical and investigational parameters as possible predictors of response. Overall drug efficacy and safety in the study population were assessed as a secondary end point.
Patients and methods

Study design
This was a spontaneous, double-blind, randomised controlled study aimed at assessing the clinical efficacy of 3 mg fixed-dose Apomorphine over a placebo in diabetic patients. The study protocol was approved by the Hospital Ethical Committee and carried out according to the principle stated in the Declaration of Helsinki.
Eligible patients were randomised to Apomorphine SL or matching placebo and reviewed after 4 weeks. Identical tablets of both the drug and the placebo were supplied by the hospital pharmacy in boxes numbered according to a computed blocking randomisation list, which was not seen by the investigators or the patients until the end of the study.
Patient eligibility
In April 2001, a clinic organised jointly by the Diabetic Unit and the Urological Clinic was set up with the specific purpose of treating ED in diabetic patients. From that date until September 2003, a consecutive series of 154 diabetic men (both type I and type II) with a history of ED, lasting at least 3 months, for which they never received treatment, were evaluated. Any major psychiatric disorder, the absence of a stable partner, penile deformities and the concomitant presence of a neurological disease other than diabetes constituted exclusion criteria. On the first outpatient appointment (visit 1), data concerning a history of ischaemic heart disease, stroke, hypertension, duration of diabetes and ED, and concomitant medications were recorded in a database. Patients with high-risk cardiovascular disease were excluded from the study. Inclusion of intermediate-risk patients depended on the cardiologist's opinion. 12 A total of 133 patients who fulfilled the initial inclusion criteria for the study signed an informed consent to undergo baseline investigations during a 2-week screening period and to be randomised to receive either Apomorphine 3 mg or equivalent placebo if eligible. Haematological investigations included total serum testosterone, Hemoglobin1Ac (Hb1Ac) assessment and lipid profile. All patients were also asked to complete the EF domain of the International Index of Erectile Function (IIEF) questionnaire. 13 ED was defined as mild, moderate or severe if the EF domain scores were between 17 and 24, 11 and 16, and o10, respectively. A dynamic Colour Doppler ultrasound (CDUS) was performed as previously described.
14 A maximum peak systolic velocity (PSV) of lower than 30 cm/s was considered indicative of arteriogenic ED, while an end diastolic velocity (EDV) of more than 5 cm/s in the presence of a normal PSV was taken to indicate a venogenic ED. 15 Artificial erectile performance was categorised into four grades by the same doctor according to objective examination criteria. A partial tumescence with inadequate rigidity was defined as grade I. A full tumescence with moderate rigidity was defined as grade II. Complete tumescence with suboptimal rigidity was scored as grade III while grade IV represented the situation of full rigidity lasting at least 20 min. 16 Glandular sensitivity was assessed using a biothesiometer. A sensitivity threshold exceeding the 2 s.d. of the nomogram reported by Breda et al 17 was defined as pathological and taken as a gross indicator of sensorial neuropathy.
Treatment
At visit 2, patients with a total serum testosterone level below the normal laboratory range value (200 ng/dl) or an EF domain score for the IIEF 424 were considered ineligible. The remaining were randomised and instructed to take one tablet sublingually 15 min before attempting sexual intercourse and to allow it to dissolve after placing it under the tongue. All patients received four sample doses of either 3 mg fixed-dose Apomorphine SL or an equivalent placebo and were told to use one tablet 'as required', not exceeding one dose in any 8-h period. A diary card was given for the patient to record the date and time a tablet was taken and the side effects. Visit 3 was scheduled after 4 weeks. On that occasion, patients were asked to complete the one-item global efficacy question (GEQ) and the EF domain of the IIEF questionnaires.
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Evaluation of efficacy and statistics
The primary efficacy variable was the response rate to the treatment in both arms, defined as a positive response to the one-item GEQ together with an improvement of at least 5 points in the EF domain of the IIEF. The GEQ asks 'Has the treatment you have been taking over the past two or four weeks improved your erections?' The EF domain of the IIEF has six questions; answers are scored from 1 (almost never/never) to 5 (almost always/always), with 0 indicating no sexual activity. Question 3 (Q3) assesses the ability to achieve an erection sufficient for sexual intercourse, while question 4 (Q4) assesses the ability to maintain an erection after penetration. Secondary efficacy variables were the change from the baseline to the control visit in the overall EF domain score and in questions 3 and 4 of the IIEF. Treatment compliance and side effects were evaluated from the patient's diary. Patients were considered for efficacy evaluation if they had taken at least two tablets.
The estimated response rate in the placebo arm was 20%. Apomorphine treatment was expected to increase this to 50% to be clinically relevant. A sample size of 102 patients (51 in each group) was required for the study to have 90% power to detect this difference at the 5% significance level (twosided). This sample size also had 90% power to detect a 10% difference in IIEF scores.
Responders and nonresponders were also subanalysed by the concomitant presence of one or more comorbid factors and several parameters indicative of the severity of both ED (duration of ED, EF domain of the IIEF, CDUS) and diabetes (time from diagnosis of diabetes and Hb1Ac). This constituted a secondary end point.
The
Results
Three patients were excluded because of abnormal testosterone values (o200 ng/dl). A total of 130 patients were randomised. No significant differences were observed between the placebo and the treatment group for any of the demographic parameters (Table 1 ). There was a balance across all levels of severity of ED, as defined by the EF domain of the IIEF, and the aetiology, according to CDUS parameters, upon entering the study. Three patients in the placebo arm and four in the treatment arm were excluded from the efficacy evaluation because of failure to use the required minimum number of Apomorphine SL in diabetic patients P Gontero et al doses. Three additional patients were lost to followup (one in the placebo arm and two in the treatment arm). In total, 120 patients (61 for the placebo group and 59 for the Apomorphine group) could be evaluated, which provided sufficient power for the analysis of efficacy.
Efficacy
Affirmative responses to the GEQ were found in 21.15% of patients in the placebo arm and 25% in the Apomorphine group (P ¼ 0.65). Similarly, the percentage of patients considered as responders according to our criteria did not significantly differ between the two groups (17.31 and 22.92% for the placebo group and the Apomorphine group, respectively, P ¼ 0.48). Mean IIEF Q3 and Q4 as well as the ED domain scores improved for both the placebo and the treatment arm over the baseline but the difference was not statistically significant. The improvement of IIEF parameters observed after Apomorphine was only marginal compared with the placebo (Table 2) . Table 3 reports on the distribution of several variables related to diabetes and ED among responders and nonresponders in both arms. Responders to Apomorphine were significantly younger and had a significantly lower Hb1Ac, while the difference was not significant for the placebo arm. Time from diagnosis of diabetes and ED as well as the IIEF EF domain score at baseline did not have a significant impact on being a responder in either of the arms. Similarly, the presence of one or more comorbidities was equally distributed among responders and nonresponders for both arms. A pharmacological erection of grade Z3 was a significant predictor of response only in the Apomorphine arm. According to the dynamic CDUS, patients who improved their EF after taking either Apomorphine or placebo had significantly higher PSV and significantly lower EDV. The finding of an abnormal penile biothesiometry was too infrequent in our study population to allow a subanalysis of responders and nonresponders.
Parameters as predictors of response
Treatment compliance and tolerability
In all, 50% of nonresponders in the placebo arm and 45% in the treatment arm failed to take all the dispensed tablets, while this was true of only 12% of responders in the placebo arm and 10% in the treatment arm. Nausea was the only recorded side effect, noted by 9% of the patients taking Apomorphine and 5% taking the placebo. No patients discontinued the treatment because of side effects. Apomorphine SL in diabetic patients P Gontero et al
Discussion
Apomorphine SL can be considered one of the currently available first-line treatment options for ED also in the diabetic population. In terms of the onset of action, it is a fast-acting drug and produces a clinical response on average within 15 min, 18 allowing for more spontaneity in sexual intercourse. Further, unlike the phosphodiesterase 5 inhibitors, the use of Apomorhine SL in patients with stable coronary artery disease who are taking nitrates is not contraindicated. Notwithstanding a well-defined safety profile, data on the efficacy of this drug in the diabetic population have been extrapolated only from subgroup analyses. Mulhall et al 11 evaluated a subgroup of 196 diabetic patients from a large cohort of 849 ED patients and reported an increase from 9% at baseline to 27.4% after treatment with Apomorphine of erections firm enough for sexual intercourse. Dula et al 10 observed no notable difference in the efficacy of 3 mg Apomorphine in the small subgroup of 30 diabetic patients compared with the global study population (46.9% of successful intercourse in the treatment arm vs 32.3% in the placebo arm).
Although preliminary studies showed an encouraging efficacy profile, there has been a progressive disaffection with the use of Apomorphine SL since its release in the European Union in 2001. A study assessing whether Apomorphine SL may still have a role in the treatment of diabetic ED is therefore appropriate since no such data have been published in the postmarketing period. The primary objective of the study was to assess the efficacy profile of the drug in the treatment of diabetic ED. The rate of affirmative response to the GEQ was only marginally higher in the treatment arm compared with the placebo arm. Similarly, the rate of responders, defined as the percentage of patients giving a positive answer to the GEQ and reporting a clinically meaningful improvement of at least 5 points in the EF domain, 18 was only slightly more pronounced in the treatment arm than in the placebo arm. The efficacy profile of 3 mg Apomorphine SL in the overall sample was lower than that reported by Dula et al 10 and Mulhall et al 11 and this may be due to the use of different efficacy end points. No significant improvement in the EF domain of the IIEF and in Q3 and Q4 scores after 3 mg Apomorphine compared with either the placebo or the baseline was observed. To maximise the potential effectiveness, dosing was initiated at 3 mg without titration in our study. Side effects were comparable to those reported using a dose-optimisation regimen, 11 with mild to moderate nausea being the only reported adverse event. Patients were given four doses, which represent the minimum number of attempts to obtain a 70% probability of successful response. 19 It may be speculated that a higher number of treatment attempts could have enhanced the cumulative proportion of responders. The diabetic population in the present study was comparable for demographic characteristics to other study series assessing the role of phosphodiesterase type 5 inhibitors. 20, 21 Comorbidities of hypertension and coronary artery disease did not seem to exceed the rate of complications reported in other study populations of ED patients. 10 Although an upper Hb1Ac level for patients to be excluded from the study was not defined, sugar control in the study population was similar to other controlled trials. 10, 20 It is therefore unlikely that selection criteria may have had an impact on the poor response rate of the present study.
As a second primary end point, it was attempted to identify factors that may help to select patients more likely to benefit from the treatment. In previous phase III studies, Apomorphine proved to be effective in patients irrespective of the aetiology and severity of ED. 10, 11 It is known from other series that the severity of diabetes ED depends upon several variables, namely Hb1Ac concentration and autonomic neuropathy. 22 As far as Sildenafil is concerned, it has been demonstrated that efficacy is independent of Hb1Ac concentrations or duration of ED and that patients with fewer diabetic complications show only marginally better IIEF scores. 20, 23 In the current study, Apomorphine responders had significantly lower Hb1Ac levels and showed a less impaired penile vascularity according to CDUS parameters. On the contrary, the IIEF score, a clinical indicator of the severity of ED, was not a predictor of treatment efficacy. No notable difference in the response rate emerged when patients were stratified according to the presence of one or more comorbid factors.
In conclusion, Apomorphine SL produced a clinically relevant erectile response in 22% of ED diabetic patients according to our efficacy parameters. These results were only marginally better than those obtained in a matched placebo group. Patients who were younger with a better glycaemic control and a lesser degree of penile haemodynamic impairment were found to have a significantly higher treatment response rate. Given these figures and the favourable tolerability profile, Apomorphine SL may still represent an alternative first-line treatment option for a subgroup of diabetic patients with various degrees of ED.
